본문 바로가기
KERD
논문KCI 등재

Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B

이혜원|한광협|박준용|김도영|안상훈|김승업|김범경|Jae Seung Lee|Mi Young Jeon
대한간학회 (The korean Association for the Study of the Liver)|2021.04|Clinical and Molecular Hepatology|제27권 제2호|pp. 295-304|DOI 10.3350/cmh.2020.0216

2

조회

0

다운로드

8

인용

0

참고문헌

키워드

Hepatitis BCarcinomaAntiviral agentHepatic fibrosisImmune toleranceHepatocellular

초록

Background/Aims: The immune-tolerant (IT) phase of chronic hepatitis B (CHB) patients is not generally indicative of antiviral therapy (AVT). We assessed and compared the risk of hepatocellular carcinoma (HCC) during the IT-phase stringently defined by a low fibrosis-4 (FIB-4) index, compared to that in patients undergoing AVT. Methods: Among 125 untreated patients that were hepatitis B e-antigen positive, hepatitis B virus-DNA >20,000 IU/mL, with normal alanine aminotransferase level from 2012 to 2018, those with a FIB-4 index of <1.45 were classified into the IT-group. The cumulative probability of HCC was estimated using Kaplan-Meier analysis. All patients were assessed until HCC development (intention-to-treat [ITT] analysis), whereas those suspected of experiencing CHB phase switch were assessed using the per-protocol (PP) and censored at the time of phase switch. Results: The cumulative probability of HCC at 1-, 3-, and 5-years among the IT-group was zero, compared to AVT-treated patients with FIB-4 indices <1.45 during the same period: 0.2%, 0.6%, and 1.4%, respectively (P=0.264 for ITT and P=0.533 for PP). Among the initially screened 125 untreated patients, those with a FIB-4 index of ≥1.45 had a higher risk of HCC compared to the IT-group (P=0.005). Furthermore, among AVT-treated patients, those with a FIB-4 index of ≥1.45 had a higher risk of HCC compared to their counterpart (P<0.001). Conclusions: The risk of HCC was negligible in the IT-group stringently defined by a low FIB-4 index. However, given that a higher HCC risk exists among untreated patients with higher FIB-4, appropriate criteria for AVT should be established.

Abstract

Background/Aims: The immune-tolerant (IT) phase of chronic hepatitis B (CHB) patients is not generally indicative of antiviral therapy (AVT). We assessed and compared the risk of hepatocellular carcinoma (HCC) during the IT-phase stringently defined by a low fibrosis-4 (FIB-4) index, compared to that in patients undergoing AVT. Methods: Among 125 untreated patients that were hepatitis B e-antigen positive, hepatitis B virus-DNA >20,000 IU/mL, with normal alanine aminotransferase level from 2012 to 2018, those with a FIB-4 index of <1.45 were classified into the IT-group. The cumulative probability of HCC was estimated using Kaplan-Meier analysis. All patients were assessed until HCC development (intention-to-treat [ITT] analysis), whereas those suspected of experiencing CHB phase switch were assessed using the per-protocol (PP) and censored at the time of phase switch. Results: The cumulative probability of HCC at 1-, 3-, and 5-years among the IT-group was zero, compared to AVT-treated patients with FIB-4 indices <1.45 during the same period: 0.2%, 0.6%, and 1.4%, respectively (P=0.264 for ITT and P=0.533 for PP). Among the initially screened 125 untreated patients, those with a FIB-4 index of ≥1.45 had a higher risk of HCC compared to the IT-group (P=0.005). Furthermore, among AVT-treated patients, those with a FIB-4 index of ≥1.45 had a higher risk of HCC compared to their counterpart (P<0.001). Conclusions: The risk of HCC was negligible in the IT-group stringently defined by a low FIB-4 index. However, given that a higher HCC risk exists among untreated patients with higher FIB-4, appropriate criteria for AVT should be established.

참고문헌 (33)

  1. Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
  2. Kumar M, "Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT", Gastroenterology, 134, pp.1376~1384 (2008)
  3. Yang HI, "Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACHB): development and validation of a predictive score", Lancet Oncol, 12, pp.568~574 (2011)
  4. Chen CF, "Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma", Gastroenterology, 141, pp.240~1248 (2011)
  5. European Association for the Study of the Liver, "EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
  6. Lok AS, "Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis", Hepatology, 63, pp.284~306 (2016)
  7. u CY, "Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study", Gastroenterology, 147, pp.143~151.e5 (2014)
  8. Varbobitis I, "The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy", Clin Mol Hepatol, 22, pp.319~326 (2016)
  9. Kim SU, "Hepatocellular carcinoma risk steadily persists over time despite long-term antiviral therapy for hepatitis B: a multicenter study", Cancer Epidemiol Biomarkers Prev, 29, pp.832~837 (2020)
  10. Terrault NA, "AASLD guidelines for treatment of chronic hepatitis B", Hepatology, 63, pp.261~283 (2016)
  11. Korean Association for the Study of the Liver, "KASL clinical practice guidelines: management of chronic hepatitis B", Clin Mol Hepatol, 22, pp.18~75 (2016)
  12. Tran TT, "Immune tolerant hepatitis B: a clinical dilemma", Gastroenterol Hepatol (N Y), 7, pp.511~516 (2011)
  13. Mason WS, "HBV DNA Integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant", Gastroenterology, 151, pp.986~998.e4 (2016)
  14. Lai M, "The clinical significance of persistently normal ALT in chronic hepatitis B infection", J Hepatol, 47, pp.760~767 (2007)
  15. Enriquez AD, "Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis", Aliment Pharmacol Ther, 26, pp.383~391 (2007)
  16. Zoulim F, "Reasons to consider earlier treatment of chronic HBV infections", Gut, 61, pp.333~336 (2012)
  17. Kim GA, "High risk of hepatocellular carcinoma and death in patients with immunetolerant-phase chronic hepatitis B", Gut, 67, pp.945~952 (2018)
  18. Vlachogiannakos J, "HBV: do I treat my immunotolerant patients?", Liver Int, 36(Suppl 1), pp.93~99 (2016)
  19. Lee HW, "Natural history of untreated HBeAg-positive chronic HBV infection with persistently elevated HBV DNA but normal alanine aminotransferase", lin Transl Gastroenterol, 11, pp.e00140~ (2020)
  20. Lee HA, "Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase", Aliment Pharmacol Ther, 52, pp.196~204 (2020)
  21. Chun HS, "Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C.", Eur J Gastroenterol Hepatol, 32, pp.378~385 (2020)
  22. Lee HW, "Prognosis of untreated minimally active chronic hepatitis B patients in comparison with virological responders by antivirals", Clin Transl Gastroenterol, 10, pp.e00036~ (2019)
  23. Lee HW, "Progression of untreated minimally active chronic HBV infection compared to inactive infection", Clin Gastroenterol Hepatol, 17, pp.2808~2810.e2 (2019)
  24. Grant BF, "Epidemiology of alcoholic liver disease", Semin Liver Dis, 8, pp.12~25 (1988)
  25. European Association for the Study of the Liver, "EASL clinical practice guidelines: management of alcohol-related liver disease", J Hepatol, 69, pp.d154~181 (2018)
  26. Tseng TC, "Fibrosis-4 index helps identify HBV carriers with the lowest risk of hepatocellular carcinoma", Am J Gastroenterol, 112, pp.1564~1574 (2017)
  27. Chan HL, "Effects of tenofovir disoproxil fumarate in hepatitis B e antigenpositive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA", Gastroenterology, 146, pp.1240~1248 (2014)
  28. Wong VW, "Four-year outcomes after cessation of tenofovir in immune-tolerant chronic hepatitis B patients", J Clin Gastroenterol, 52, pp.347~352 (2018)
  29. Marcellin P, "Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B", N Engl J Med, 359, pp.2442~2455 (2008)
  30. Kim HS, "Association between level of fibrosis, rather than antiviral regimen, and outcomes of patients with chronic hepatitis B", Clin Gastroenterol Hepatol, 14, pp.1647~1656.e6 (2016)
  31. San Juan López Cristina, "Characterization and evaluation of liver fibrosis grade in patients with chronic hepatitis B virus infection and normal transaminases", Clinical and Molecular Hepatology, 24(4), pp.384~391 (2018), 대한간학회
  32. Wang HY, "Distinct hepatitis B virus dynamics in the immunotolerant and early immunoclearance phases", J Virol, 84, pp.3454~3463 (2010)
  33. Mi Young Jeon, "Assessment of fibrotic burden among chronic hepatitis B virus-infected patients with normal transaminase level", Clinical and Molecular Hepatology, 24(4), pp.367~369 (2018), 대한간학회

관련 논문AI추천

Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase김영석, 유정주, Han Ah Lee, Jieun Lee, Ji Eun Moon, Sang Gyune Kim, Soo Young Park, Yeon Seok Seo, Yu Rim Lee대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B이혜원, Grace Chung-Yan Lui, Grace Lai-Hung Wong, Henry Lik-Yuen Chan, Lilian Yan Liang, Terry Cheuk-Fung Yip, Vicki Wing-Ki Hui, Vincent Wai-Sun Wong, Yee-Kit Tse대한간학회 · Clinical and Molecular Hepatology2021 · 제27권 제3호Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patientsAnlin Ma, Bingqiong Wang, Guofeng Chen, Hongxin Piao, Hong You, Huiguo Ding, Hwai-I Yang, Jialing Zhou, Jidong Jia, Shuyan Chen, Tongtong Meng, Wen Xie, Xiaojuan Ou, Xiaoning Wu, Xiaoqian Xu, Yameng Sun, Yuanyuan Kong대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제3호A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels강원석, 곽금연, 김경아, 김정희, 백승운, 백용한, 신동현, 안중현, 윤정환, 이동현, 이정훈, 이준혁, 이지현, 조광철, 최문석거트앤리버 소화기연관학회협의회 · Gut and Liver2017 · 제11권 제4호Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommendGrace Lai-Hung Wong대한간학회 · Clinical and Molecular Hepatology2018 · 제24권 제2호Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status김미나, Beom Kyung Kim, Do Young Kim, Jun Yong Park, Kwang-Hyub Han, Sang Hoon Ahn, Seong Gyu Hwang, Seung Up Kim거트앤리버 소화기연관학회협의회 · Gut and Liver2019 · 제13권 제2호

이 간행물의 다른 논문 (14건)

Evaluation and Management of Extrahepatic Manifestations of Nonalcoholic Fatty Liver DiseaseDonghee Kim, Aijaz Ahmed, Wijarnpreecha Karn, Elizabeth S. Abypp. 221-235Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospectsHideki Iwamoto, Takuji Torimurapp. 236-245Current and future strategies for the treatment of chronic hepatitis COmar Alshuwaykh, Paul Y. Kwopp. 246-256From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?Korean NAFLD Study Group, Yuri Cho, Soung Won Jeong, Jin-Woo Lee, Seong Hee Kang, Seung Up Kimpp. 257-269A need for patient-centered care in managing patients with liver cirrhosisYoon Eileen L.pp. 270-272
원문 보기